FDA approves Lilly’s Omvoh: A breakthrough for ulcerative colitis treatment

Pallavi Madhiraju- October 27, 2023 0

The U.S. Food and Drug Administration (FDA) has sanctioned Eli Lilly and Company's Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), making it the pioneering ... Read More

Eli Lilly receives FDA response letter for eczema treatment lebrikizumab

Pallavi Madhiraju- October 2, 2023 0

Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for lebrikizumab, a treatment aimed at addressing moderate-to-severe ... Read More

Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal

Pallavi Madhiraju- June 20, 2023 0

Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More

Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib

pharmanewsdaily- June 15, 2020 0

Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the ... Read More

Lilly to acquire US dermatology drug company Dermira for $1.1bn

pharmanewsdaily- January 13, 2020 0

Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 ... Read More